Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
Trial ID or NCT#
NCT03137381
Status
RECRUITING
Purpose
This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.
Official Title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Eligibility Criteria
Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Definitive diagnosis of alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted. - At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline. - Clinical lab results within the normal range
Exclusion Criteria:
- - Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp. - Treatment with systemic immunosuppressive medications or biologics. - Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening or during the study
Investigator(s)
Justin M Ko, MD, MBA
Dermatologist,
Melanoma specialist,
Cutaneous oncology specialist,
Hair loss specialist,
Psoriasis specialist
Clinical Professor, Dermatology
Contact us to find out if this trial is right for you.
Contact
Michelle Kim
650-498-4880
View on ClinicalTrials.gov
